Since the presence of MTH1 protects the brain, long-term inhibition may lead to neurodegenerative diseases associated with oxidative stress, so it is important to consider how to reduce this possible disadvantage of using MTH1 inhibitors in cancer therapy. Here, NUDT1 is linked to cancer.